NCT04498741 - Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 8, 2020

Primary Completion Date

May 27, 2021

Study Completion Date

June 1, 2021

Conditions

RSV Infection

Interventions

DRUG

EDP-938

Subjects will receive EDP-938 once daily on Days 10 through 27 (Part 1)

DRUG

EDP-938

Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 2)

DRUG

EDP-938

Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 3)

DRUG

Tacrolimus

Subjects will receive tacrolimus once daily on Day 1 and Day 24

DRUG

Dabigatran

Subjects will receive dabigatran once daily on Day 1 and Day 13

DRUG

Rosuvastatin

Subjects will receive rosuvastatin once daily on Day 1 and Day 13

DRUG

EDP-938

Subjects will receive EDP-938 once daily on Days 3 through 16 (Part 4)

DRUG

Midazolam

Subjects will receive midazolam once daily on Day 1 and Day 16

Trial Locations (1)

Pharmaceutical Research Associates, Inc.,, Lenexa